Antibiotic dosing issues in lower respiratory tract infection: Population-derived area under inhibitory curve is predictive of efficacy

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue SUPPL. A, 1999, Pages 55-63

  Highet, Vicki Sue ^a   Forrest, Alan ^a   Ballow, Charles H ^a   Schentag, Jerome J ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b Millard Fillmore Gates Circle Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; DATA BASE; DILUTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY FUNCTION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PREDICTION; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

AGED; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CEFTAZIDIME; CEPHALOSPORINS; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIPENEM; MALE; MICROBIAL SENSITIVITY TESTS; PENICILLINS; PIPERACILLIN; PREDICTIVE VALUE OF TESTS; RESPIRATORY TRACT INFECTIONS; THIENAMYCINS; TREATMENT OUTCOME;

EID: 0033049151     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Peloquin, C. A., Cumbo, T. J., Nix, D. E., Sands, M. F. & Schentag, J. J. (1989). Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Archives of Internal Medicine 149, 2269-73.
2. Carson, H. B., Heller, A. S., Koch, T. B., Walczak, P. & Schentag, J. J. (1983). Antibiotic penetration in abdominal infection; a case of tobramycin failure responsive to moxalactam. Drug Intelligence and Clincal Pharmacy 17, 277-9.
3. Ellner, P. D. & Neu, H. C. (1981). The inhibitory quotient: a method for interpreting minimum inhibitory concentration data. Journal of the American Medical Association 246, 1575-8.
4. Drake, T. R. A., Hackbarth, C. J. & Sande, M. A. (1983). Value of serum tests in combined drug therapy of endocarditis. Antimicrobial Agents and Chemotherapy 24, 653-7.
5. Schumacher, G. E. (1983). Pharmacokinetic and microbiologic evaluation of dosage regimens for newer cephalosporins and penicillins. Clinical Pharmacy 2, 448-57.
6. Barriere, S. L., Ely, E., Kapusnik, J. E. & Gambertoglio, J. G. (1985). Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve. Journal of Antimicrobial Chemotherapy 16, 49-59.
7. Wolfson, J. S. & Swartz, M. N. (1985). Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy. New England Journal of Medicine 312, 968-75.
8. Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S. & Craig, W. A. (1988). Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. Journal of Infectious Diseases 158, 831-47.
9. Eagle, H., Fleischman, R. & Musselman, A. D. (1950). Effect of schedule of administration on the therapeutic efficacy of penicillin. Importance of the aggregate time penicillin remains at effectively bactericidal levels. American Journal of Medicine 9, 280-99.
10. Schentag, J. J., Nix, D. E. & Adelman, M. H. (1991). Mathematical examination of dual individualization principles (I): Relationship between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. Drug Intelligence and Clincal Pharmacy 25, 1050-7.
11. Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C. & Schentag, J. J. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37, 1073-81.
12. Goss, T. F., Forrest, A., Nix, D. E., Ballow, C. H., Birmingham, M. C., Cumbo, T. J. et al. (1994). Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Annals of Pharmacotherapy 28, 863-8.
13. Fink, M. P., Snydman, D. R., Niederman, M. S., Leeper, K. V., Johnson, R. H., Heard, S. O. et al. (1994). Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrobial Agents and Chemotherapy 38, 547-57.
14. Amsden, G. W., Ballow, C. H. & Schentag, J. J. (1993). Population pharmacokinetic methods to optimize antibiotic effects. Drug Investigation 5, 256-68.
15. Forrest, A., Ballow, C. H., Nix, D. E., Birmingham, M. C. & Schentag, J. J. (1993). Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrobial Agents and Chemotherapy 37, 1065-72.
16. Hoffken, G., Lode, H., Prinzing, C., Borner, K. & Koeppe, P. (1985). Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrobial Agents and Chemotherapy 27, 375-9.
17. Breiman, L., Friedman, J. H., Olshen, R. & Stone, C. J. (1984). Classification and Regression Trees. Wadsworth, Belmont, CA.
18. National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A3. NCCLS, Villanova, PA.
19. Gengo, F. M., Mannion, R. W., Nightingale, C. H. & Schentag, J. J. (1984). Integration of pharmacokinetics and pharmacodynamics of methicillin in the curative treatment of experimental endocarditis. Journal of Antimicrobial Chemotherapy 14, 619-31.
20. Paladino, J. A., Sperry, H. F., Backes, J. M., Gelber, J. A., Serrianne, D. A., Cumbo, T. J. et al. (1991). Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. American Journal of Medicine 91, 462-70.
21. Chin, N.-X., Novelli, A. & Neu, H. C. (1988). In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones. Antimicrobial Agents and Chemotherapy 32, 656-62.
22. Hyatt, J. M., Luzier, A. B., Forrest, A., Ballow, C. H. & Schentag, J. J. (1997). Modeling the response of pneumonia to antimicrobial therapy. Antimicrobial Agents and Chemotherapy 41, 1269-74.
23. Ballow, C. H. & Schentag, J. J. (1992). Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagnostic Microbiology and Infectious Disease 15, 37S-42S.
24. Paladino, J. A. & Fell, R. E. (1994). Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Annals of Pharmacotherapy 28, 384-9.